Crataegus orientalis subsp. orientalis
Crataegus orientalis subsp. orientalis · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Crataegus orientalis subsp. orientalis is a distinctive botanical species that holds significant interest in pharmacological research. Scientific investigations have focused specifically on the bioactive potential found within the plant's leaf structure. Through the process of creating an ethanol extract, researchers have been able to isolate key compounds for study. These concentrated preparations have demonstrated notable antithrombotic activities in various experimental models. Consequently, this subspecies represents a promising subject for developing new therapeutic agents related to blood coagulation.
- Synonyms
- Mespilus Tanacetifolia Var. Typica · Mespilus Odoratissima · 15 more
- Common names
- Not available
- Family
- Rosaceae
- Distribution
- Not available
- Plant Parts
- Leaf
Classification
Common Names
Crataegus orientalis subsp. orientalis is a distinct botanical specimen known widely by its scientific designation. In English-speaking regions, this plant is commonly referred to as the Oriental Hawthorn. Those locating the species within German-speaking territories will recognize it by its local name, Orientalischer Weißdorn. These various naming conventions help gardeners and researchers identify the specific subspecies across different linguistic landscapes. Understanding these relationships is essential for accurate documentation and global botanical communication.
Sources: Catalogue of Life (COL)
Synonyms
Crataegus orientalis subsp. orientalis is a complex botanical taxon that is associated with several different scientific names. Throughout various classifications, it has been identified by the synonym Crataegus odoratissima. Researchers also recognize several specific varieties that fall under its umbrella, such as Crataegus orientalis var. flabellata and Crataegus orientalis var. obtusata. Furthermore, the plant is linked to the synonyms Crataegus orientalis var. sanguinea and Crataegus orientalis var. tournefortii. Understanding these shifting nomenclatures is essential for accurate plant identification and study.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Crataegus orientalis subsp. orientalis belongs to the vast kingdom Plantae, representing a unique branch of the natural world. Within this kingdom, the plant is classified under the class Equisetopsida, placing it among diverse vascular species. It further descends through the order Rosales, which connects it to many familiar flowering plants. As a member of the Rosaceae family, it shares structural characteristics with other well-known rose varieties. Ultimately, this specific subspecies is defined by its placement within the genus Crataegus.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Rosales |
| Family | Rosaceae |
| Genus | Crataegus |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Crataegus orientalis subsp. orientalis exhibits a broad and diverse geographical range that spans multiple continents. Within the Asia-Temperate region, this subspecies is found across the Caucasus and Transcaucasus, extending into Central Asia and Uzbekistan. Its presence also stretches through Western Asia, specifically within the borders of Türkiye. Moving toward the European continent, the plant establishes itself in Northern Europe, including the United Kingdom. Specifically, its distribution encompasses the landscapes of Great Britain and Ireland.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Biological Activities
Crataegus orientalis subsp. orientalis exhibits notable antithrombotic activity, making it a subject of significant interest for cardiovascular health research. Studies utilizing an ethanol extract of its leaves have demonstrated a capacity to inhibit thrombosis in carrageenan-induced mouse models. While lower doses showed limited impact, higher concentrations of 200 and 300 mg/kg significantly reduced tail thrombosis during the initial stages of observation. These findings suggest that the plant's rich composition of flavonoids and triterpene acids may contribute to its medicinal efficacy. Ultimately, this research highlights the potential of the species as a source for developing new therapeutic agents to prevent intravascular complications.
Compounds
Conditions
Crataegus orientalis subsp. orientalis, specifically its ethanol leaf extract, demonstrates significant antithrombotic activity in the carrageenan-induced mice tail thrombosis model. When administered at doses of 200 and 300 mg/kg, the extract effectively inhibits the formation of tail thrombosis in vivo. While the 100 mg/kg dose did not show significant results compared to control groups, the higher dosages provided measurable therapeutic benefits. The most pronounced antithrombotic effects were observed at the 24-hour mark, though the efficacy of these doses decreased during the 48 and 72-hour intervals. Ultimately, these findings suggest that this plant species serves as a potent agent for treating induced thrombosis in mice.
Preparations
Crataegus orientalis subsp. orientalis is prepared as an ethanol extract to investigate its medicinal properties. This specific extract was derived from the leaves of the plant to test its biological effects. Researchers utilized the ethanol extract to evaluate antithrombotic activity within a carrageenan-induced mice tail thrombosis model. The study specifically examined how different doses of this ethanol extract influenced the length of tail thrombosis over several time intervals. Ultimately, the results demonstrated that the prepared ethanol extract significantly inhibited thrombosis in vivo.
Parts used
Crataegus orientalis subsp. orientalis is a medicinal plant species widely recognized for its potential in treating cardiovascular diseases. Research specifically highlights the use of its leaf extracts to investigate therapeutic properties such as antithrombotic activity. In experimental models involving carrageenan-induced thrombosis, ethanol extracts from these leaves have demonstrated significant inhibitory effects. Studies indicate that higher doses of the leaf extract can effectively reduce tail thrombosis in mice during specific time intervals. Consequently, the leaves of this subspecies represent a promising source for developing new agents to manage intravascular complications.